...
首页> 外文期刊>Nutrition, metabolism, and cardiovascular diseases: NMCD >Prostaglandin E1 versus lumbar sympathectomy in the treatment of peripheral arterial occlusive disease: randomised study of 86 patients.
【24h】

Prostaglandin E1 versus lumbar sympathectomy in the treatment of peripheral arterial occlusive disease: randomised study of 86 patients.

机译:前列腺素E1与腰椎交感神经切除术治疗周围动脉闭塞性疾病:随机研究86例患者。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND AIM: The aim of this study was to compare the effects of a pharmacological and a surgical vasodilatatory therapy in the treatment of chronic arterial diseases of the lower limbs. METHODS AND RESULTS: After giving their informed consent, 40 patients were randomised to receive a slow (approximately 2-hour) infusion of 40 microg of prostaglandin E1 twice daily for 28 days (group A), and 46 were randomised to undergo lumbar sympathectomy, including the second and third ganglion. Twenty-four (60%) of the patients in group A experienced complete remission, seven (17.5%) were partial responders, and nine (22.5%) failed to respond. Of the 46 patients in group B, 29 (63%) experienced complete remission, seven (15.2%) were partial responders, and 10 (21.7%) failed to respond. CONCLUSIONS: Broadly similar results were obtained with the two types of treatment, both of which are indicated mainly in Fontaine stages IIB and III (non-advanced), particularly when revascularising therapy is impossible or excessively risky. The two strategies can be advantageously combined with direct revascularisation surgery and may therefore constitute a first-line approach favouring subsequent therapy.
机译:背景与目的:这项研究的目的是比较药理学和外科血管扩张治疗在下肢慢性动脉疾病治疗中的作用。方法和结果:在获得知情同意后,将40例患者随机分为两组,分别每天缓慢(约2小时)输注40μg前列腺素E1,每天两次,持续28天(A组),其中46例患者随机接受腰椎交感神经切除术,包括第二和第三神经节。 A组中的二十四名患者(60%)完全缓解,七名(17.5%)为部分缓解,九名(22.5%)未缓解。 B组的46名患者中,有29名(63%)完全缓解,其中7名(15.2%)为部分缓解,而10名(21.7%)未缓解。结论:两种治疗方法均获得大致相似的结果,这两种治疗方法主要在II级和III级Fontaine阶段(未进行),尤其是在无法进行血管重建治疗或风险过大的情况下。这两种策略可以有利地与直接血运重建术相结合,因此可以构成有利于后续治疗的一线方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号